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ABSTRACT
INTRODUCTION: Several studies demonstrate the presence of quantitative and functional abnormalities 
in the dendritic cell (DC) subsets in patients with multiple myeloma (MM). The inhibitory effect of IL-6, 
TGF-β, IL-10 and beta-2-microglobuline (beta-2-MG) is highly suspected. 
PURPOSE: The aim of the study was to evaluate the myeloid and plasmacytoid dendritic cells (MDC and 
PDC) in newly diagnosed patients with MM in correlation with various biological markers. 
MATERIALS AND METHODS: Thirty patients with newly diagnosed MM were included in the study. All 
the laboratory parameters were obtained at the time of diagnosis. Three colour flowcytometry with ILT3/
lin/CD11c was used for the detection of the two peripheral blood dendritic cell (PBDC) subsets. The plasma 
level of IL6 was detected by ELISA (Standard Curve Range: 2-200pg/ml); the beta-2-MG- by the immunotur-
bidimetric test.
RESULTS: The median age of patients was 61.5 years (36-89). The mean M-protein concentration was 
46.5±16.2 g/l. IgG kappa was detected in 15 patients, IgG lambda-in 4, IgA kappa-in 7, IgA lambda-in 3. The 
mean level of beta-2-MG was 7.0±5.7mg/l (1.82–22.49 mg/l ); beta-2-MG was used to determine the stage 
according to the ISS. The mean level of IL6 was 27.73±21.47pg/ml (4.6–72.5 pg/ml). The percentage of MDC 
and PDC was significantly lower in the periferal blood of patients with MM in comparison to healthy sub-
jects (0.08%±0.09% vs 0.21%±0.02% and 0.04%±0.03% vs 0.16%±0.01%, respectively). A statistically signifi-
cant difference was found between the percentage of MDC and PDC in the different stages. There was a neg-
ative correlation between MDC and PDC and the levels of beta-2-MG (p=0.02 and p=0.02), as well as between 
MDC and the IL6 levels (p=0.04). No correlation was found between MDC, PDC, levels of M-protein and the 
type of paraprotein.
CONCLUSION: Our results demonstrate the relationship between peripheral blood DC, IL6 and beta-
2-MG and confirm the published data for the inhibitory effect of the two factors on DC differentiation and 
maturation in vitro. The monitoring of beta-2-MG and IL6 may have clinical implication as a predictor of 
the immune system status as well as for the yield of harvested DCs for vaccination.
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INTRODUCTION
Dendritic cells (DCs) are sparsely distribut-
ed bone marrow-derived cells that are continuously 
produced from haematopoietic stem cells (5). As the 
most potent antigen-presenting cells, DCs are spe-
cialized in the uptake, processing, transport and pre-
sentation of antigens to T cells (6). Variations among 
the tissue distribution, as well as differences in their 
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phenotype and function, indicate the existence of a 
heterogeneous DC population that in periferal blood 
(PB) is represented by two subsets, namely the my-
eloid DC (MDC) precursors and the plasmacytoid 
DC (PDC) (14). Although their developmental rela-
tionship has not been established, it is likely that they 
represent distinct lineages of functionally diverse 
immature DCs (5,8). MDC and PDC induce polar-
ization of naïve T cells, driving T-helper 1 (Th1) and 
Th2 immune response respectively (9,13). Defects in 
immune response are often reported in patients with 
multiple myeloma (MM). Dendritic cells (DCs) are 
key effectors in promoting cellular immunity and 
are potential vectors for immunotherapy. Contradic-
tory results have been obtained regarding the num-
ber, phenotypic status and functionality of DCs from 
MM patients. Some studies demonstrate that the lev-
el of DCs in these patients is normal (3,10,11), while 
other studies show a reduced number and function-
al impairment of MM DCs and the inhibitory role of 
IL-6, TGF-β, IL-10 is broadly discussed (1,2,4,7,12). 
The role of beta-2-MG in the MM pathogene-
sis is well established. Recently, a new, international 
classification method was utilized for myeloma prog-
nosis, The International Staging System (ISS), using 
a combination of serum beta-2-MG and serum albu-
min for staging the disease. Beta-2-MG is supposed 
to be a negative regulator of the immune system. An 
interesting study demonstrates that high serum con-
centration of the protein inhibits generation of func-
tional monocyte derived dendritic cells in vitro (17). 
The aim of the present study was to evaluate the 
myeloid and plasmacytoid dendritic cells in newly 
diagnosed patients with MM and search for a corre-
lation with various biological markers such as beta-
2-MG, Il-6, the type and the amount of paraprotein. 
MATERIALS AND METHODS
Patients
Thirthy patients with MM, diagnosed at the 
University Hospital, Varna were studied, 14 males 
and 16 females, with median age of 61.5 years (range, 
36–89 years). Ten healthy volunteers served as con-
trols. Samples of heparinized blood were drawn from 
patients at the time of diagnosis and before the ad-
ministration of any treatment. Informed consent was 
obtained from both patients and normal donors. The 
mean M-protein concentration was 46.5±16.2 g/l. 
IgG kappa was detected in 15 patients, IgG lambda-
in 4, IgA kappa-in 7, IgA lambda-in 3 patients. 
Flow cytometric analysis
Blood DCs were identified by three-colour 
staining, performed on PBMC, using the following 
MoAbs: ILT3-PE-cyanin 5 (PC5) (Immunotech, Vil-
lepinte, France), CD11c-PE (PharMingen; BD, Er-
embodegen, Belgium) and fluorescein isothiocya-
nate (FITC)-labelled MoAbs against lineage markers 
CD14, CD16, CD19 and CD56 (Immunotech). Cells 
that were not labelled by these lineage markers were 
designated as lin−.
IL-6 ELISA
The test was performed using a standard Kit 
Human IL-6 with Pre-Coated Plate, eBioscience, 
(Standard Curve Range: 200-2pg/ml) according to 
the protocol provided. 
Serum beta-2-MG
Beta-2-MG was evaluated in serum from pa-
tients with MM using the immunoturbidimetric test.
Statistical analysis
The data sets were compared by independent 
two-tailed t-tests. P<0.05 was considered significant. 
The Pearson correlation test was used to assess linear 
relationships between samples. SPSS Statistics 17.0 
software was used.
RESULTS
Blood DC reduction in MM patients
Circulating blood DC subsets were analyzed 
at diagnosis on PB mononuclear cells using the lin-
eage markers, CD11c and ILT3. According to the 
expression of CD11c, two populations of lin−/ILT3+ 
cells were observed: lin−/ILT3+/CD11c+ MDCs and 
lin−/ILT3+/CD11c− PDCs (Fig. 1A). In the group of 
the MM patients, the percentage of both DC sub-
sets was significantly reduced compared to controls 
(MDC: 0.08%±0.09% vs 0.21%±0.02% and PDC: 
0.04%±0.03% vs 0.16%±0.01%, p<0.001). 
Corelation of MDC and PDC with serum 
beta-2-MG 
The mean level of serum beta-2-MG in patients 
with MM was 7.0±5.7mg/l (1.82–22.49 mg/l). Using 
this value, the stage of the disease was determined 
according to ISS. Five patients were in stage I, five in 
stage II, and twenty in stage III. A statistically signif-
icant diference was found between the levels of MDC 
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and PDC in the diferent stages (Fig. 2). A negative 
corelation was found between the serum beta-2-MG 
and PBDC subsets (Pearson Correlation for MDC 
and beta-2-MG -0.47, р=0.02, and for PDC and beta-
2-MG -0.47, р=0.02) (Fig. 3). 
Corelation of MDC and PDC with IL-6
The mean level of Il-6 was 27.73±21.47pg/ml 
(4.6–72.5 pg/ml). Based on the hystogram patients 
were devided in three groups according to the IL-6 
level: 0-20 pg/ml, 20-40 pg/ml, and >40 pg/ml. A sta-
tistically significant diference was found between the 
levels of MDC in the three diferent groups (Fig 4). 
There was a negative correlation between MDC and 
the IL6 levels (Pearson Correlation -0.48, р=0.04). 
No correlation was found between PDC and IL-6 
(Pearson Correlation B2M -0.03, р=0.4) (Fig.5).
Fig. 1. Examples of the flow cytometric analysis of the circulating DC subsets in a healthy volunteer and an MM pa-
tient. Blood DCs were identified by three-colour staining performed on PBMCs using the following MoAbs: ILT-3-PC5, 
CD11c-PE and FITC-labelled MoAbs against lineage markers CD14, CD16, CD19 and CD56. According to the expression 
of CD11c, two populations of lin−/ILT3+ cells were observed: lin−/ILT3+/CD11c+ MDCs and lin−/ILT3+/CD11c− PDCs (A). 
Distribution of the percentage and mean values of PBDCs in healthy donors and MM patients (B).
Fig. 2. Statistically significant diference was found be-
tween the levels of MDC and PDC in the diferent stag-
es of MM
Fig.3. A corelation between the serum beta-2-MG and 
PBDC subsets. Pearson Correlation for MDC and beta-2-
MG (-0,47, р=0,02), and for PDC and beta-2-MG (-0,47, 
р=0,02)
Fig. 4. A comparison between the pecentage of MDC and 
PDC in the groups defined according to Il-6 level (0-20 pg/
ml, 20-40 pg/ml, and >40 pg/ml).
Fig. 5. The correlation between MDC and the IL6 levels 
(Pearson Correlation -0,48, р=0,04) and PDC and IL-6 
(Pearson Correlation -0,48, р=0,04).
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No correlation was found between MDC, PDC, 
levels of M-protein and the type of paraprotein.
DISCUSSION
In the present study we found that the two 
PBDC subsets are decreased in patients with new-
ly diagnosed MM. In a similar study, Ratta M et al. 
demonstrate that PBDCs from MM patients are not 
only lower in absolute numbe, but also functional-
ly defective, partially because of IL-6-mediated in-
hibition of development (12). Another study shows 
that MM patients have a 50% reduced blood lev-
el of MDC, but a DC-precursor level within normal 
range. Furthermore, GM-CSF and IL-4 ex vivo stim-
ulated DC demonstrate an impaired up-regulation of 
the co-stimulatory molecule CD80 and the adhesion 
molecule CD54 (4).  Hyashy T et al. found that sera 
from bone marrow of MM patients inhibited induc-
tion of DCs, evidenced by both phenotype and only 
weak stimulation of T-cell proliferation. Anti–vas-
cular endothelial growth factor (anti-VEGF) and/or 
anti–interleukin 6 (anti–IL-6) antibodies neutralized 
this inhibitory effect, confirming that VEGF and IL-
6, at least in part, mediate immunosuppression in 
MM patients (7). Our results demonstrate the nega-
tive relationship between peripheral blood MDC and 
IL6 and confirm in vivo the published data for the 
inhibitory effect of this factor on DC differentiation 
and maturation in vitro.
There is evidence for the suppressive effect of 
beta-2-MG on DC generation in vitro (17); howev-
er, this effect is only suspected for MM patients. In 
the present study we show that beta-2-MG negatively 
correlates with both MDC and PDC in patients with 
MM. 
Various studies have been performed in order 
to identify the ideal source of DCs from MM pa-
tients for use in vaccination approaches (2, 3, 11, 16). 
The analysis of samples following chemotherapy and 
transplantation demonstrated an increased expres-
sion of HLA molecules, suggesting that this time-
point is optimal for harvest and use in vaccination 
(1).
In this context the monitoring of beta-2-MG 
and IL6 may have clinical implication as a predictor 
of the immune system status during the course of the 
disease. It may also help to determine the most ade-
quate time point for DCs harvesting for generation 
of pure, functional, and potentially proliferating DCs 
for further use in vaccination.
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